Lasa Supergenerics
NSE: LASA · ISIN INE670X01014 · Healthcare
₹4.22−0.22 (−4.95%)
Monday 9 November, 12:14 IST. Delayed. Source: Yahoo Finance.
Price chart
₹4.22 −0.22 (−4.95%) today
The day
- Previous close
- ₹4.44
- Open
- ₹4.44
- Day high
- ₹4.44
- Day low
- ₹4.22
Listed on NSE since 21 September 2017.
Key numbers
- Market value
- ₹21.14 Cr
- EPS (trailing)
- ₹-0.80
- Price to book
- 0.43
- Dividend yield
- 0.00%
- Debt to equity
- 0.20
- Profit margin
- -253.8%
- Beta
- 0.68
- Volume today
- 53,701
- Average volume
- 19,699
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹129.57 Cr | ₹-38.62 Cr |
| FY24 | ₹104.34 Cr | ₹-21.73 Cr |
| FY25 | ₹142.45 Cr | ₹-14.76 Cr |
| FY26 | ₹25.14 Cr | ₹-34.09 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹1 Cr | ₹-4 Cr | – |
| Q4 FY26Jan–Mar 2026Audited | ₹-13.15 L | ₹-4 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹2 Cr | ₹-3 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹3 Cr | ₹-6 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹20 Cr | ₹-21 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹39 Cr | ₹-14 Cr | – |
Source: Lasa Supergenerics’s results filed with NSE, standalone (the company alone). Net profit is the share of Lasa Supergenerics’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹38 Cr | ₹40 Cr |
| Inventories | ₹2 Cr | ₹4 Cr |
| Owed by customers | ₹4.12 L | ₹2 Cr |
| Cash and equivalents | ₹28.78 L | ₹28.83 L |
| Total assets | ₹66 Cr | ₹72 Cr |
| Borrowings | ₹10 Cr | ₹7 Cr |
| Total liabilities | ₹17 Cr | ₹15 Cr |
| Shareholders’ equity | ₹50 Cr | ₹56 Cr |
Source: Lasa Supergenerics’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Lasa Supergenerics
Lasa Supergenerics Limited engages in the manufacturing API bulk drugs products in India and internationally. It offers API products, such as fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, 2,6-diiodo-4-nitrophenol, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide; and Other API products. The company also provides animal feed ingredients; and reagents for therapeutic use. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Ratnagiri
- Employees
- 9
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Lasa Supergenerics in the last day or two.
Dividends and corporate actions
All companies- Annual General Meeting
Action · ex-date 20 September 2024
- Annual General Meeting
Action · ex-date 20 September 2023
- Annual General Meeting/Dividend - Re 0.25 Per Share
Dividend · ex-date 16 September 2022
- Annual General Meeting/Dividend - Rs 0.25 Per Share
Dividend · ex-date 15 September 2021
- Annual General Meeting
Action · ex-date 17 September 2020
- Annual General Meeting
Action · ex-date 19 September 2019
- Annual General Meeting
Action · ex-date 17 September 2018
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.